This economic evaluation estimates the 10-year net fiscal impact of expanded Medicare coverage for glucagon-like peptide-1 (GLP-1) receptor agonists for obesity treatment. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.